[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350976-105":59,"doc-detail-350976-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","dysregulated-expression-of-the-tumor-suppressor-p14arf-in-cancer-provides-an-effective-target-for-tcr-t-cell-therapeutics","Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics","","Background: The CDKN2A gene encodes p16INK4A and p14ARF tumor suppressors that normally protect against malignant transformation by inducing cell-cycle arrest and apoptosis. Many cancers paradoxically overexpress these proteins after loss of negative feedback, particularly p14ARF in p53-inactivated tumors. Methods: The study evaluates feasibility of targeting dysregulated p16INK4A/p14ARF with TCR-T therapeutics using HLA-A*02:01 peptide screening, TCR isolation, functional assays, and in vivo efficacy and safety models. Results identify a p14ARF epitope and show potent tumor killing without detectable on-target toxicity. Conclusions: p14ARF is a promising target for future TCR-T therapies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dysregulated-expression-of-the-tumor-suppressor-p14arf-in-cancer-provides-an-effective-target-for-tcr-t-cell-therapeutics/350976/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dysregulated-expression-of-the-tumor-suppressor-p14arf-in-cancer-provides-an-effective-target-for-tcr-t-cell-therapeutics/350976.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does this study address in cancer immunotherapy?","Question",{"text":113,"@type":114},"The study addresses the limited availability of high-quality, cancer-selective target antigens for TCR-engineered T cells, focusing on tumor suppressor proteins that are dysregulated in cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did the researchers identify a candidate p14ARF target for TCR-T cells?",{"text":118,"@type":114},"They analyzed p16INK4A- and p14ARF-derived peptides for HLA-A*02:01 presentation and recognition by CD8+ T cells, then isolated antigen-specific TCRs and evaluated their performance in functional assays and tumor models.",{"name":120,"@type":111,"acceptedAnswer":121},"What safety finding supports the use of the p14ARF-directed TCR-T approach?",{"text":122,"@type":114},"Targeting p14ARF-expressing cells did not result in detectable on-target toxicity in an in vivo safety model.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350976,1790193998,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Open access  \nTo cite: Schmitt TM, Furiya K, Black C, et al. Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics. Journal for ImmunoTherapy of Cancer 2026;14:e013520 . doi:10 . 1136/ jitc-2025-013520  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013520](jitc-2025-013520)) .  \nPDG and AGC contributed equally.  \nAccepted 21 January 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Thomas M Schmitt; [tschmitt@fredhutch.org](tschmitt@fredhutch.org)  \nOriginal research  \nDysregulated expression of the tumor suppressor p14ARF in cancer providesan effective target for TCR-T  \ncell therapeutics  \nThomas M Schmitt  ,1 Kelsey Furiya,1 Cheryl Black,1 Angie Vazquez,1  \nJaishree Sharma,1 Menna Hailemariam,1 Daniel H Paushter,1 Lam Trieu,1 Jennifer Lam,1 Bo Lee,1 Kavya Rakhra,2 Kerry A Whalen  ,2 Naveen K Mehta,2 Karsten Sauer,2 Patrick A Baeuerle,2 Jennifer S Michaelson,2 Philip D Greenberg,1,3 Aude G Chapuis  4,5  \nABSTRACT  \nBackground The CDKN2A gene encodes two canonical tumor suppressors, p16INK4A and p14ARF, which safeguard cells from malignant transformation by inducing cell cycle arrest and apoptosis in response to aberrant growth signals. Paradoxically, many cancers overexpress these proteins when downstream effectors that enforce negative feedback regulation are lost or inactivated. For example, p14ARF, which regulates p53 activation, is aberrantly expressed in more than 50% of tumors with inactivating p53 mutations. Here, we evaluated the feasibility of targeting dysregulated p16INK4A and p14ARF expression using TCR-T cell therapeutics.  \nMethods We analyzed a panel of p16INK4A-and p14ARFderived peptides for HLA-A*02:01-associated presentation and recognition by CD8+ T cells. Antigen-specific T cell receptors were isolated from healthy donor repertoiresand expressed in primary T cells to assess specificity, functional avidity, tumor recognition, and safety using in vitro T cell functional assays, in vivo tumor models, and an in vivo safety model.  \nResults We identified a unique and well-presented p14ARF epitope that was consistently detected in the HLAA*02:01-associated immunopeptidome of cancer biopsies but not in normal tissues. High-avidity ARF-specific TCRs were isolated from the peripheral repertoire of healthy donors, and TCR-transduced T cells mediated potent tumor cell killing in vitro and in vivo in preclinical models. Furthermore, targeting p14ARF-expressing cells did not result in detectable on-target toxicity in an in vivo safety model.  \nConclusions These findings demonstrate the feasibility of targeting dysregulated tumor suppressor proteins with TCR-T cell therapeutics and identify p14ARF as a promising target for future therapies.  \nINTRODUCTION  \nTCR-engineered T cells offer a powerful approach to treating solid tumors. However, the scarcity of high-quality, cancer-selective target antigens remains a major obstacle to the  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ TCR-engineered T cell therapies have shown encouraging clinical activity, but identifying tumorselective antigens that can be safely and effectively targeted remains a central challenge. Tumor suppressor proteins are often aberrantly expressed in cancer following disruption of negative feedback regulation, as exemplified by p53-dependent control of p14ARF and Rb-dependent control of p16INK4A; however, they have been largely overlooked as targets for TCR-based immunotherapy.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study identifies an HLA-A*02:01-restricted p14ARF-derived epitope that is efficiently processed and presented by tumor cells and recognized by T","cbCaighUUhcORfKe","https://ap.wps.com/l/cbCaighUUhcORfKe","pdf",7000735,17,"English","# Abstract\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What problem does this study address in cancer immunotherapy?\",\"answer\":\"The study addresses the limited availability of high-quality, cancer-selective target antigens for TCR-engineered T cells, focusing on tumor suppressor proteins that are dysregulated in cancer.\"},{\"question\":\"How did the researchers identify a candidate p14ARF target for TCR-T cells?\",\"answer\":\"They analyzed p16INK4A- and p14ARF-derived peptides for HLA-A*02:01 presentation and recognition by CD8+ T cells, then isolated antigen-specific TCRs and evaluated their performance in functional assays and tumor models.\"},{\"question\":\"What safety finding supports the use of the p14ARF-directed TCR-T approach?\",\"answer\":\"Targeting p14ARF-expressing cells did not result in detectable on-target toxicity in an in vivo safety model.\"}]","Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics | PDF",1790092173,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/535c6c3f88fbfcd817809b27d32d8cab.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51517cdf826a46064bbe873bf63149fc.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/696eaba5a78fd92914be1c6a5f552347.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8beed2e0b6eda9bcc633d11ac951d2ff.webp",980,1306]